Pretreatment of Human Mesenchymal Stem Cells with Pioglitazone Improved Efficiency of Cardiomyogenic Transdifferentiation and Cardiac Function
The efficacy of transplantation of default human marrow‐derived mesenchymal stem cells (MSCs) was modest. In this study, our challenge was to improve the efficacy of MSC transplantation in vivo by pretreatment of MSCs with pioglitazone. MSCs were cultured with or without medium containing 1 μM of pi...
Saved in:
Published in | Stem cells (Dayton, Ohio) Vol. 29; no. 2; pp. 357 - 366 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.02.2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The efficacy of transplantation of default human marrow‐derived mesenchymal stem cells (MSCs) was modest. In this study, our challenge was to improve the efficacy of MSC transplantation in vivo by pretreatment of MSCs with pioglitazone. MSCs were cultured with or without medium containing 1 μM of pioglitazone before cardiomyogenic induction. After cardiomyogenic induction in vitro, cardiomyogenic transdifferentiation efficiency (CTE) was calculated by immunocytochemistry using anti‐cardiac troponin‐I antibody. For the in vivo experiments, myocardial infarction (MI) at the anterior left ventricle was made in nude rats. Two weeks after MI, MSCs pretreated with pioglitazone (p‐BM; n = 30) or without pioglitazone (BM; n = 17) were injected, and then survived for 2 weeks. We compared left ventricular function by echocardiogram and immunohistochemistry to observe cardiomyogenic transdifferentiation in vivo. Pretreatment with pioglitazone significantly increased the CTE in vitro (1.9% ± 0.2% n = 47 vs. 39.5% ± 4.7% n = 13, p < .05). Transplantation of pioglitazone pretreated MSCs significantly improved change in left ventricular % fractional shortening (BM; −4.8% ± 2.1%, vs. p‐BM; 5.2% ± 1.5%). Immunohistochemistry revealed significant improvement of cardiomyogenic transdifferentiation in p‐BM in vivo (BM; 0% ± 0% n = 5, vs. p‐BM; 0.077% ± 0.041% n = 5). Transplantation of pioglitazone‐pretreated MSCs significantly improved cardiac function and can be a promising cardiac stem cell source to expect cardiomyogenesis. STEM CELLS 2011; 29:357–366 |
---|---|
Bibliography: | First published online in S Disclosure of potential conflicts of interest is found at the end of this article. C EXPRESS December 9, 2010. TEM Author contributions: D.S.: conception and design, collection and assembly of data, final approval of manuscript; I.T.: conception and design, collection and assembly of data, final approval of manuscript; S.M.: conception and design, administrative support, collection and assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; N.N.: conception and design, collection and assembly of data, final approval of manuscript; N.H.: conception and design, collection and assembly of data; H. Tsuji: conception and design, collection and assembly of data, final approval of manuscript; H. Tsuruta: conception and design, collection and assembly of data, final approval of manuscript; K.S.: conception and design, collection and assembly of data, final approval of manuscript; Y.T.: provision of study material or patients, collection and assembly of data, final approval of manuscript; S.O.: financial support, administrative support, final approval of manuscript; A.U.: financial support, administrative support, final approval of manuscript. D.S. and I.T. contributed equally to this article. ELLS Telephone: 81‐3‐3353‐1211 (ext 62310); Fax: 81‐3‐3353‐2502 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1066-5099 1549-4918 |
DOI: | 10.1002/stem.574 |